stockrowDianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
Follow DNTH
Alert me
Dianthus Therapeutics, Inc. (DNTH) EV/EBITDA
Dianthus Therapeutics, Inc. has no meaningful EV/EBITDA: its trailing twelve-month EBITDA is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 10.4× (December 2023) — the current reading is the lowest in ten years.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 2.3× | 0.74% |
| FY2022 | 2.3× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 13 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| LEGN Legend Biotech Corporation Sponsored ADR compare | n/m |
| DFTX Definium Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| TVTX Travere Therapeutics, Inc. compare | n/m |
| DNTH Dianthus Therapeutics, Inc. | n/m |
| MANE Veradermics Incorporated compare | n/m |
| CRSP CRISPR Therapeutics AG compare | n/m |
| COGT Cogent Biosciences, Inc. compare | n/m |
| Biotechnology industry median | 0.7× |
| Healthcare sector median | 8.5× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on DNTH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement